Risk impact of edoxaban in the management of stroke and venous thromboembolism - Wikidata - wikimedia - TriplyDB

Risk impact of edoxaban in the management of stroke and venous thromboembolism

Risk impact of edoxaban in the management of stroke and venous thromboembolism

http://www.wikidata.org/entity/Q26738846

about

Risk impact of edoxaban in the management of stroke and venous thromboembolism

http://www.wikidata.org/entity/Q26738846

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@ast

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@en

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@nl

type

label

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@ast

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@en

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@nl

prefLabel

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@ast

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@en

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@nl

P1433

Q26738846-D08587C5-A8F4-4A81-A715-E348A0E7BE64

P1476

Q26738846-821844EB-321A-486E-94D3-719D39FF81DF

P2093

Q26738846-3EF9CB22-368E-4305-A292-E2866EE36400

Q26738846-4B2C1781-1097-4349-AEA4-41B4C540D055

Q26738846-75906ACB-3C1A-4A78-B361-6AA48366291F

P275

Q26738846-9DD5C05F-4493-4A18-AF47-093FC546A209

P2860

Q26738846-0A4296F6-B492-4D42-AB8B-DA3C12B854D7

Q26738846-0D076DFB-86F2-428F-9239-AF6580066FE1

Q26738846-186BDB23-866B-4A59-82F5-2CB370D847EF

Q26738846-19A0ADCB-3BD5-439B-B9B7-CCD92DB71A92

Q26738846-1CED31EC-871A-4EAE-AADC-41BF7BEFC909

Q26738846-2BC58484-5754-4897-A796-036CE536818A

Q26738846-2E6D3003-5EAD-47D1-A6D0-71C990FE6E06

Q26738846-3791D362-9DF4-4F9C-9D22-671EE65D015E

Q26738846-3D7EB8FF-6D6C-4827-92D9-34EE4ED4CAD1

Q26738846-40B4DDB1-07B6-4B6E-9722-7AB58EFF8950

P304

Q26738846-A21B9AC6-801D-4553-B545-5494A9A1B895

P31

Q26738846-99871F0E-F645-401F-AD48-E2A9E8692A85

Q26738846-EE8816A3-218F-4E71-98FF-491B48D87A1B

P3181

Q26738846-8F5482B6-2399-433F-827A-0A6AA06E92CE

P356

Q26738846-D6AABA5F-A349-491F-A7FF-B4EAD39C4F85

P407

Q26738846-6A7432DE-2DEE-4C07-967A-8B88E7CE0135

P478

Q26738846-816EEC8A-A159-4E17-BEF4-8DD65E7A1861

P5008

Q26738846-76459C4A-CBBA-41F0-A6CF-D24111B43103

P577

Q26738846-489FD110-2628-456F-BEC4-96AAA7721022

P698

Q26738846-A7E79C53-8F1D-4A1A-8CF0-C3518EFAD1C9

P921

Q26738846-030AABB5-1D43-4C3B-BC95-BFBEF3CA75B0

Q26738846-330AA57C-DC03-41B3-8FA8-762364A12491

Q26738846-682A8316-42E1-46B0-ABDE-811343E5FC31

Q26738846-C461B6DE-4FB4-4F49-AB57-1CC118BFA703

Q26738846-C50D8BC0-3BEB-4E8E-AC79-8D73381541CA

Q26738846-F1BE78BF-E8F4-4E4B-A909-BA8A200C6E2E

Q26738846-F1D30752-E58D-4C87-A072-CA989359A35B

P932

Q26738846-115C7EDD-535A-4571-AFB6-7A3C5AC52EF6

P3181

P356

P1433

Vascular Health and Risk Management

P1476

Risk impact of edoxaban in the management of stroke and venous thromboembolism

@en

P2093

Ashok Handa

http://www.w3.org/2001/XMLSchema#string

John Matthew O'Callaghan

http://www.w3.org/2001/XMLSchema#string

Katherine V Hurst

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.

Evolving use of new oral anticoagulants for treatment of venous thromboembolism

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.

P304

329-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4151481

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/VHRM.S94679

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27563246

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

cerebrovascular disease

mechanism of action

venous thromboembolism

atrial fibrillation

P932

4986674

http://www.w3.org/2001/XMLSchema#string